Historical and epidemiologic background of human premalignant breast disease

Journal of Mammary Gland Biology and Neoplasia

Volumn 5, Issue 4, 2000, Pages 341-349

  Page, D L ^a   Jensen, R A ^b   Simpson, J F ^a   Dupont, W D ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Premalignancy; Risk

Indexed keywords

ESTROGEN; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

AGE; BREAST; BREAST BIOPSY; BREAST CANCER; BREAST HYPERPLASIA; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOMA IN SITU; DISEASE COURSE; DISEASE MARKER; ESTROGEN THERAPY; FOLLOW UP; GENE AMPLIFICATION; GENE EXPRESSION; HISTOLOGY; HUMAN; INVASIVE CARCINOMA; MICROSCOPIC ANATOMY; MOLECULAR GENETICS; MORBIDITY; ONCOGENE NEU; PRECANCER; PREDICTION; PREVALENCE; RELIABILITY; REVIEW; SEX DIFFERENCE; TUMOR GROWTH;

BREAST NEOPLASMS; FEMALE; HUMANS; PRECANCEROUS CONDITIONS; RISK; RISK FACTORS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034458576     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009521726605     Document Type: Review

References (36)

1. Benign breast changes and the risk for subsequent breast cancer - An update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists
2. Breast cancer epidemiology: Summary and future directions
3. Benign breast diseases and premalignant breast disease
4. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin
5. Risk factors for breast cancer in women with proliferative breast disease
6. Atypical hyperplastic lesions of the female breast. A long follow-up study
7. Anatomic markers of human premalignancy and risk of breast cancer
8. A prospective study of benign breast disease and risk of breast cancer
9. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy
10. The influence of margin width on local control of ductal carcinoma in situ of the breast
11. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
12. Estrogen replacement therapy in women with a history of proliferative breast disease
13. Risk of breast cancer in women with palpable breast cysts: A prospective study. Edinburgh Breast Group
14. ABC of breast diseases: Congenital problems and aberrations of normal breast development and involution
15. Long-term risk of breast cancer in women with fibroadenoma
16. Mammographic densities and the prevalence and incidence of histological types of benign breast disease. Reference Pathologists of the Canadian National Breast Screening Study
17. Mammographic parenchymal patterns: A marker of breast cancer risk
18. Premalignant and malignant disease of the breast: The roles of the pathologist
19. Invasive breast cancer risk in women with sclerosing adenosis
20. Radial scars in benign breast-biopsy specimens and the risk of breast cancer
21. Ductal carcinoma in situ - The focus for prevention, screening, and breast conservation in breast cancer
22. Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage
23. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types
24. BRCA2 hereditary breast cancer pathophenotype
25. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions
26. Preneoplastic lesions in the human breast
27. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions
28. Lobular neoplasia of the breast: Higher risk for subsequent invasive cancer predicted by more extensive disease
29. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia
30. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial
31. Loss of heterozygosity and microsatellite instability in breast hyperplasia. No obligate correlation of these genetic alterations with subsequent malignancy
32. Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia
33. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer
34. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk
35. Biomarkers in benign breast disease: Risk factors for breast cancer
36. Ductal involvement by cells of atypical lobular hyperplasia in the breast: A long-term follow-up study of cancer risk